Identification of Breath Biomarkers in Esophageal Cancer

Prior treatment

• Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.);

Other illness

• Patients with hematogenous metastasis disease at diagnosis;
• Patients who cannot tolerate chemoradiotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia.
• The physical condition is not enough to provide 0.5L exhalation at one time.

Other

• Female patients who are pregnant or lactating;
• Inability to provide informed consent due to psychological, familial, social and other factors;

• Histologically confirmed squamous cell carcinoma of the esophagus;
• Absence of hematogenous metastasis disease, confirmed by endoscopic ultrasound (EUS) and PET-CT scan (according to UICC TNM version 8);
• Age at diagnosis \>18 years;
• No prior cancer therapy;
• Estimated life expectancy \>6 months;
• Eastern Cooperative Oncology Group performance status ≤ 2
• No history of concomitant or previous malignancy;
• The function of important organs meets the following requirements: a. white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥ 100×109/L; c. hemoglobin ≥ 9g/dL; d. serum albumin ≥ 2.8g/dL; e. total bilirubin ≤ 1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; f. serum creatinine ≤ 1.5×ULN or creatinine clearance rate \>60 mL/min;
• Ability to understand the study and sign informed consent.